| benchmark test |
|
|
|
|
♡
|
| human benchmark |
|
|
|
|
♡
|
| fsrh guidelines |
|
|
21 |
|
♡
|
| therapeutic guidelines |
|
|
60 |
|
♡
|
| etg therapeutic guidelines |
|
|
67 |
|
♡
|
| VIPONLYVIPO LYVIPONLYV PONLY |
|
|
77 |
|
♡
|
| VIPONLYV PONLYVIPONLYV PON |
|
|
28 |
|
♡
|
| VIPONLYV PONLYVIPONLYV PONLY |
|
|
23 |
|
♡
|
| VIPONLYVIPON |
|
|
|
|
♡
|
| VIPONLYVIP |
|
|
|
|
♡
|
| VIP NLYVIPONLY |
|
|
24 |
|
♡
|
| VIPONL VIPONLYVIP |
|
|
31 |
|
♡
|
| VIPO LYVIPONLYV |
|
|
22 |
|
♡
|
| VIPONL VIPONLYVIPON YVIPONLYVI |
|
|
80 |
|
♡
|
| VIPONLYV PONLYVIP NLYVIPONLY |
|
|
60 |
|
♡
|
| VIPONLYVI |
|
|
|
|
♡
|
| VIPO LYVIPONLYV |
|
|
25 |
|
♡
|
| VIPONLYVIP |
|
|
21 |
|
♡
|
| VIPO LYVIPONLYV |
|
|
25 |
|
♡
|
| VIPONLYV PONLYVIP NLYVIPONLY |
|
|
6 |
|
♡
|